Maria João Gouveia

ORCID: 0000-0003-3747-5520
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Parasites and Host Interactions
  • Helminth infection and control
  • Parasite Biology and Host Interactions
  • Medication Adherence and Compliance
  • HIV/AIDS drug development and treatment
  • Research on Leishmaniasis Studies
  • Pregnancy and Medication Impact
  • Pharmaceutical Practices and Patient Outcomes
  • Drug Transport and Resistance Mechanisms
  • Parasitic infections in humans and animals
  • RNA Interference and Gene Delivery
  • Pharmacological Effects and Toxicity Studies
  • Health Systems, Economic Evaluations, Quality of Life
  • Pharmacogenetics and Drug Metabolism
  • Glutathione Transferases and Polymorphisms
  • COVID-19 Impact on Reproduction
  • HIV, Drug Use, Sexual Risk
  • Advanced biosensing and bioanalysis techniques
  • Pregnancy and preeclampsia studies
  • Receptor Mechanisms and Signaling
  • Evacuation and Crowd Dynamics
  • HIV/AIDS Research and Interventions
  • Amoebic Infections and Treatments
  • Trypanosoma species research and implications
  • Antimicrobial Peptides and Activities

Universidade do Porto
2012-2024

National Institute of Health Dr. Ricardo Jorge
2015-2024

Rede de Química e Tecnologia
2017-2021

Centre for Health Technology and Services Research
2020-2021

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto
2019-2020

Institute of Biomedical Science
2020

Universidade da Madeira
2020

Universidade Católica Portuguesa
2013-2016

Hospital Geral de Bonsucesso
2008

The liver fluke Opisthorchis felineus is a member of the triad epidemiologically relevant species trematode family Opisthorchiidae, and causative agent opisthorchiasis felinea over an extensive range that spans regions Eurasia. International Agency for Research on Cancer classifies infection with flukes viverrini Clonorchis sinensis as group 1 agents major risk factor cholangiocarcinoma. However, carcinogenic potential O. less clear. Here, we present findings support inclusion in Group list...

10.1093/carcin/bgx042 article EN Carcinogenesis 2017-05-04

The potential benefits of drug repurposing have gained attention as an alternative to developing de novo drugs. using central nervous system (CNS) drugs anticancer has been explored in several types human cancers, such breast and colon cancer, among others. Here, we examine the effect CNS sertraline, paroxetine, chlorpromazine on squamous carcinoma cells bladder (UM-UC-5). After exposing UM-UC-5 increased concentrations each for 48 h, assessed their metabolic activity MTT assay. Based those...

10.3390/pharmaceutics16020212 article EN cc-by Pharmaceutics 2024-01-31

This study aimed to model the pharmacokinetics of lamotrigine (LTG) and efavirenz (EFV) in pregnant women using physiologically based pharmacokinetic (PBPK) pregnancy-specific PBPK (p-PBPK) models. For lamotrigine, adult demonstrated accurate predictions for parameters. Predictions area under curve (AUC) peak plasma concentration (Cmax) generally agreed well with observed values. During pregnancy, accurately predicted AUC Cmax a prediction error (%PE) less than 25%. The evaluation EFV...

10.3390/pharmaceutics16091163 article EN cc-by Pharmaceutics 2024-09-03

Schistosomiasis is a neglected tropical disease, endemic in 76 countries, that afflicts more than 240 million people. The impact of schistosomiasis on infertility may be underestimated according to recent literature. Extracts Schistosoma haematobium include estrogen-like metabolites termed catechol-estrogens down regulate estrogen receptors alpha and beta responsive cells. In addition, schistosome derived induce genotoxicity result estrogen-DNA adducts. These catechol estrogens the...

10.1371/journal.pone.0096774 article EN cc-by PLoS ONE 2014-05-21

Schistosomiasis is a major neglected tropical disease. Treatment for schistosomiasis with praziquantel (PZQ), which effective against the parasite, by itself not capable to counteract infection-associated disease lesions including hepatic fibrosis. There pressing need novel therapies. Due their biological properties, antioxidant biomolecules might be useful in treating and reverting associated pathological sequelae. Here, we investigated therapy approach based on combination of anthelmintic...

10.3390/biom9020054 article EN cc-by Biomolecules 2019-02-05

Treatment of schistosomiasis has relied on the anthelmintic drug praziquantel (PZQ) for more than a generation. Despite its celebrated performance treatment and control other platyhelminth infections, some shortcomings inability this to counteract disease sequelae prompts need novel therapeutic strategies. Using host-parasite model involving Biomphalaria glabrata Schistosoma mansoni we established mechanical transformation S. cercariae into newly transformed schistosomula (NTS) characterized...

10.1186/s13071-019-3566-9 article EN cc-by Parasites & Vectors 2019-06-20

Infections classified as group 1 biological carcinogens include the helminthiases caused by Schistosoma haematobium and Opisthorchis viverrini. The molecular mediators underlying infection with these parasites cancer remain unclear. Although carcinogenesis is a multistep process, we have postulated that release metabolites including oxysterols estrogen-like interact host cell DNA. How why parasite produce/excrete A gene encoding CYP enzyme was identified in schistosomes opisthorchiids....

10.1186/s13027-019-0257-2 article EN cc-by Infectious Agents and Cancer 2019-11-29

Abstract Earlier reports revealed oxysterol metabolites of Opisthorchis spp. liver fluke origin conjugated with DNA bases, suggesting that the generation these DNA-adducts may underlie mutagenicity and carcinogenicity infection food-borne pathogens. Here, we employed liquid chromatography-mass spectrometry to investigate, compare contrast spectrograms soluble extracts from Fasciola hepatica adult worms bile ducts cattle those O. viverrini felineus experimentally infected hamsters. F. shared...

10.1017/exp.2020.38 article EN cc-by-nc-nd Experimental Results 2020-01-01
Coming Soon ...